STA
SRPT icon

Summit Trail Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Summit Trail Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Sell
13,858
-1,312
-9% -$24.8K ﹤0.01% 1376
2026
Q1 		$330K Sell
15,170
-3,216
-17% -$62.2K ﹤0.01% 1279
2025
Q4 		$396K Buy
+18,386
New +$387K 0.01% 1145
2018
Q1 		– Sell
-730
Closed -$45K – 1487
2017
Q4 		$45K Buy
+730
New +$38.7K 0.01% 845

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Summit Trail Advisors's SRPT Position: Q2 2026 in Review

Summit Trail Advisors reduced its Sarepta Therapeutics (SRPT) stake by 8.6% in Q2 2026, selling an estimated $24.8K and leaving 13,858 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Summit Trail Advisors first reported a position in SRPT in Q4 2017 and has held it in 4 quarters since. The position peaked at $396K in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Summit Trail Advisors held 13,858 shares of Sarepta Therapeutics worth $249K as of Q2 2026.
  • Summit Trail Advisors sold 1,312 Sarepta Therapeutics shares in Q2 2026, an estimated $24.8K.
  • Sarepta Therapeutics made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1376 holding.
  • Summit Trail Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • Summit Trail Advisors's Sarepta Therapeutics position peaked at $396K in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.